Analysis of the frequency of detection of hypercholesterolemia, carotid atherosclerosis and lipid-lowering therapy prescription in young adults under 45 years old according to the Duplex registry database
Authors
-
Oleg V. Gaisenok
United Hospital with Outpatient Clinic
https://orcid.org/0000-0002-2379-0450
DOI:
https://doi.org/10.18413/rrpharmacology.9.10007Abstract
Aim of the study to analyze the detection of hypercholesterolemia (HCHL) and carotid atherosclerosis (CAS), verified by duplex scanning of the carotid arteries (DSCA) in young adults (YA), and to evaluate the lipid-lowering therapy (LLT) prescription among them according to the local registry database.
Material and Methods: The Duplex registry database was used for this study (n=2548). YA up to 45 years old were selected for the final analysis (n=351).
Results: HCHL (> 5 mmol/L) was detected in 68.9% of patients (n=241), and only 9.5% of them received LLT (n=23). CAS was detected in 12.8% (n=45), only 17.8% of them had received LLT (n=8). Men and women differed 1.5 times by the incidence of CAS in this age range: 15.7% (30 out of 191) vs 9.4% (15 out of 160), p=0.05. Men also generally have a higher prevalence of other risk factors/diseases: HCHL (78.0% (n=149) vs 58.1% (n=93) in women, p=0.00004), hypertension (AH) (15.7% (n=30) vs 9.4% (n=15) in women, p=0,05), history of myocardial infarction (MI) (1,6% (n=3) vs 0% (n=0) in women, ns). Signs that had a significant impact on LLT intake were the following: CAS (OR 2.8 [1.09;6.6] p=0.036); AH (OR 3.1 [1.32; 7.16] p=0.009); HCHL (> 5 mmol/L) (OR 4.2 [1.12; 26.83] p=0.06); HCHL (ICD-10 code E78) (OR 5.4 [2.04; 13.7] p=0.0003); MI history (OR 22.3 [1.65;675.5] p=0.009).
Conclusion: The insufficient LLT prescription in young adults with HCHL and CAS was ascertained in the present study. The use of imaging methods to clarify the degree of cardiovascular risk is advisable for low and intermediate risk patients, which include young adults. DSСA is the main method for subclinical atherosclerosis verification. LLT should be prescribed to all YA patients with CAS (in the absence of contraindications).
Graphical Abstract
Graphical Abstract
Keywords:
lipid-lowering therapy, young adults, hypercholesterolemia, carotid atherosclerosis, duplex scanning, registryReferences
Akhmedzhanov NM, Nebieridze DV, Safaryan AS, Vygodin VA, Shuraev AYu, Tkacheva ON, Lishuta AS (2015) Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): part I. Rational Pharmacotherapy in Cardiology [Ratsional’naya Farmakoterapiya v Kardiologii] 11(3): 253–260. https://doi.org/10.20996/1819-6446-2015-11-3-253-260 [in Russian]
Arora S, Stouffer GA, Kucharska-Newton AM, Qamar A, Vaduganathan M, Pandey A, Porterfield D, Blankstein R, Rosamond WD, Bhatt DL, Caughey MC (2019) Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction. Circulation 139(8): 1047–1056. https://doi.org/10.1161/CIRCULATIONAHA.118.037137[PubMed] [PMC]
Bedi US, Singh M, Singh PP, Bhuriya R, Bahekar A, Molnar J, Khosla S, Arora R (2010) Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal-medial thickness: a meta-analysis of randomized controlled trials. Journal of Cardiovascular Pharmacology and Therapeutics 15(3): 268–273. https://doi.org/10.1177/1074248410369110 [PubMed]
Berdalin AB, Vishnyakova AYu, Gubsky IL, Golovin DA, Lelyuk VG (2021) State of intra- and extracranial arteries, white matter and cerebral cortex in asymptomatic hypertensive patients. Cardiovascular Therapy and Prevention [Kardiovaskulyarnaya Terapiya i Profilaktika] 20(7): 2768. https://doi.org/10.15829/1728-8800-2021-2768 [in Russian]
Chou R, Dana T, Blazina I, Daeges M, Jeanne TL (2016) Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA 316(19): 2008–2024. https://doi.org/10.1001/jama.2015.15629 [PubMed]
Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, Lear SA, Teo K, Yeates KE, Lanas F, Li W, Hu B, Lopez-Jaramillo P, Gupta R, Kumar R, Mony PK, Bahonar A, Yusoff K, Khatib R, Kazmi K, Dans AL, Zatonska K, Alhabib KF, Kruger IM, Rosengren A, Gulec S, Yusufali A, Chifamba J, Rangarajan S, McKee M, Yusuf S; PURE Study (2020). Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Global Health 5(11): e002640. https://doi.org/10.1136/bmjgh-2020-002640 [PubMed] [PMC]
Crouse JR III, Raichlen JS, Riley WA (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis the METEOR trial. JAMA 297(12): 1344–1353. https://doi.org/10.1001/jama.297.12.1344 [PubMed]
D'Erasmo L, Commodari D, Di Costanzo A, Minicocci I, Polito L, Ceci F, Montali A, Maranghi M, Arca M (2020) Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study. Nutrition, Metabolism, and Cardiovascular Diseases 30(11): 2027–2035. https://doi.org/10.1016/j.numecd.2020.06.028 [PubMed]
Elis A, Leventer-Roberts M, Bachrach A, Lieberman N, Durst R, Knobler H, Balicer R (2020) The characteristics of patients with possible familial hypercholesterolemia-screening a large payer/provider healthcare delivery system. QJM: An International Journal of Medicine 113(6): 411–417. https://doi-org.eres.qnl.qa/10.1093/qjmed/hcz327 [PubMed]
European Carotid Surgery Trialists’ Collaborative Group (1998) Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351(9113): 1379–1387. https://doi.org/10.1016/S0140-6736(97)09292-1 [PubMed]
Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, Wilson C, Stylianou M, Howard WJ (2008) Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. Journal of the American College of Cardiology 52(25): 2198–2205. https://doi.org/10.1016/j.jacc.2008.10.031 [PubMed] [PMC]
Gaisenok O, Martsevich S, Tripkosh S, Lukina Y (2015) Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. Revista Portuguesa de Cardiologia 34(2): 111–116. https://doi.org/10.1016/j.repc.2014.08.021 [PubMed]
Gaisenok OV, Kurnosov PA, Leonov AS, Zateeyshikov DA (2018) Screening of familial hypercholesterolemia among patients in age under 40 years old exposed by duplex scanning of carotid arteries, by the local registry data. Therapeutic Archive [Terapevticheskii Arkhiv] 90(9): 37–41. https://doi.org/10.26442/terarkh201890937-41
Gaisenok O, Drapkina O (2022) Gender differences in the detection of carotid atherosclerosis: DUPLEX registry cross-sectional study results. Monaldi Archives for Chest Disease 92(4): 2128. https://doi.org/10.4081/monaldi.2022.2128[PubMed]
Högberg D, Kragsterman B, Björck M, Tjärnström J, Wanhainen A (2014) Carotid artery atherosclerosis among 65-year-old Swedish men – a population-based screening study. European Journal of Vascular and Endovascular Surgery 48(1): 5–10. https://doi.org/10.1016/j.ejvs.2014.02.004 [PubMed]
Ivanova OA, Kuklin SG, Sizova SS, Novoselova TA, Gaifullina LR (2021) Comparative effectiveness of statin therapy in patients with hypertension of high and very high cardiovascular risk in actual clinical practice in Irkutsk. Cardiovascular Therapy and Prevention [Kardiovaskulyarnaya Terapiya i Profilaktika] 20(7): 3073. https://doi.org/10.15829/1728-8800-2021-3073 [in Russian]
Joyce N, Wellenius GA, Dore DD, Newburger JW, Zachariah JP (2015) Patterns of lipid lowering therapy among children ages 8-20 years. The Journal of Pediatrics 167(1): 113–9.e1. https://doi.org/10.1016/j.jpeds.2015.04.004 [PubMed] [PMC]
Kaveshnikov VS, Serebryakova VN, Trubacheva IA, Shalnova SA (2019). Carotid atherosclerosis severity in unorganized adult population. Rational Pharmacotherapy in Cardiology [Ratsional’naya Farmakoterapiya v Kardiologii] 15(1): 84–89. https://doi.org/10.20996/1819-6446-2019-15-1-84-89 [in Russian]
Korneva VA, Kuznetsova TYu, Karpova ES, Rupasova KI (2015). Treatment of patients with severe dyslipidemia in real clinical practice. Rational Pharmacotherapy in Cardiology [Ratsional’naya Farmakoterapiya v Kardiologii] 11(4): 380–384. https://doi.org/10.20996/1819-6446-2015-11-4-380-384 [in Russian]
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 41(1): 111–188. https://doi.org/10.1093/eurheartj/ehz455 [PubMed]
Martsevich SYu, Kutishenko NP, Lukina YuV, Lukyanov MM, Drapkina OM (2020) Observational studies and registers. Their quality and role in modern evidence-based medicine. Cardiovascular Therapy and Prevention [Kardiovaskulyarnaya Terapiya i Profilaktika] 20(2): 2786. https://doi.org/10.15829/1728-8800-2021-2786 [in Russian]
Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N (2010). Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Archives of Internal Medicine 170(12): 1024–1031. https://doi.org/10.1001/archinternmed.2010.182 [PubMed]
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364): 1149–1158. https://doi.org/10.1016/S0140-6736(03)12948-0 [PubMed]
Sibley CT, Vavere AL, Gottlieb I, Cox C, Matheson M, Spooner A, Godoy G, Fernandes V, Wasserman BA, Bluemke DA, Lima JA (2013) MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart 99(22): 1675–1680. http://dx.doi.org/10.1136/heartjnl-2013-303926 [PubMed] [PMC]
Tabas I, Williams KJ, Borén J (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116(16): 1832–1844. https://doi.org/10.1161/CIRCULATIONAHA.106.676890[PubMed]
Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators (2011) Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378(9798): 1231–1243. https://doi.org/10.1016/S0140-6736(11)61215-4 [PubMed]
Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, Liu T, Yu L, Zhang S, Mony P, Swaminathan S, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear S, Anand S, Wielgosz A, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusoff K, Ismail N, Iqbal R, Rahman O, Rosengren A, Yusufali A, Kelishadi R, Kruger A, Puoane T, Szuba A, Chifamba J, Oguz A, McQueen M, McKee M, Dagenais G; PURE Investigators (2014) Cardiovascular risk and events in 17 low-, middle-, and high-income countries. The New England Journal of Medicine 371(9): 818–827. https://doi.org/10.1056/NEJMoa1311890 [PubMed]
Zyryanov SK, Fitilev SB, Vozzhaev AV, Shkrebniova II, Landyshev NN, Voronko YG, Lutsenko AM (2020) Lipid-lowering therapy in outpatients of different ages with coronary artery disease. Cardiovascular Therapy and Prevention [Kardiovaskulyarnaya Terapiya i Profilaktika] 19(5): 2654. https://doi.org/10.15829/1728-8800-2020-2654 [in Russian]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Research Results in Pharmacology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Русский
English
